Axillary Recurrence in Sentinel Lymph Node Negative Mastectomy Patients at 16 Years Median Follow Up: Natural History in the Absence of Radiation

IF 2.9 3区 医学 Q2 ONCOLOGY Clinical breast cancer Pub Date : 2024-08-03 DOI:10.1016/j.clbc.2024.07.010
Heidi S. Santa Cruz, Francys C. Verdial, Julia N. Shanno, Alexandra J. Webster, Rachel B. Jimenez, Tawakalitu O. Oseni, Tolga Ozmen, Rebecca M. Kwait, Michele A. Gadd, Michelle C. Specht, Barbara L. Smith
{"title":"Axillary Recurrence in Sentinel Lymph Node Negative Mastectomy Patients at 16 Years Median Follow Up: Natural History in the Absence of Radiation","authors":"Heidi S. Santa Cruz, Francys C. Verdial, Julia N. Shanno, Alexandra J. Webster, Rachel B. Jimenez, Tawakalitu O. Oseni, Tolga Ozmen, Rebecca M. Kwait, Michele A. Gadd, Michelle C. Specht, Barbara L. Smith","doi":"10.1016/j.clbc.2024.07.010","DOIUrl":null,"url":null,"abstract":"Axillary recurrence following lumpectomy with a negative sentinel lymph node biopsy (SLNB) is rare, possibly due to routine use of whole breast radiation. In this study, we characterized the rate of any axillary recurrence among mastectomy patients with a negative SLNB and no adjuvant radiation therapy. We identified women who underwent mastectomy with SLNB for early-stage breast cancer (1999-2005) and included patients with pathologically negative nodes and no axillary dissection or adjuvant radiation. The primary outcome was ipsilateral axillary recurrence. A total of 234 women, median age 50 years, underwent 242 mastectomies. Histology showed 112 (46%) invasive cancers, 16 (7%) ductal carcinoma in-situ (DCIS) with microinvasion, and 114 (47%) pure DCIS. Cancers were predominantly estrogen receptor positive (59%) and moderate (41%) or high grade (32%). A mean of 2 final sentinel nodes were excised (range 1-6) and 21 patients (9%) had isolated tumor cells on SLNB pathology. At 16 years median follow up (range 1-22 years), 3 patients (1.2%) developed an isolated axillary failure, and 1 had concurrent axillary and chest wall recurrences (total axillary recurrence rate 1.7%). Three of four axillary recurrences occurred in patients with moderate or high-grade estrogen receptor-positive DCIS without invasion on mastectomy histology. Median time to axillary recurrence was 70.5 months (range 29-132 months). Axillary recurrence is rare after a negative SLNB, even in the absence of adjuvant radiation. This supports the safety of forgoing additional surgery or radiation to the axilla in the early-stage breast cancer and a negative SLNB.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"1 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2024.07.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Axillary recurrence following lumpectomy with a negative sentinel lymph node biopsy (SLNB) is rare, possibly due to routine use of whole breast radiation. In this study, we characterized the rate of any axillary recurrence among mastectomy patients with a negative SLNB and no adjuvant radiation therapy. We identified women who underwent mastectomy with SLNB for early-stage breast cancer (1999-2005) and included patients with pathologically negative nodes and no axillary dissection or adjuvant radiation. The primary outcome was ipsilateral axillary recurrence. A total of 234 women, median age 50 years, underwent 242 mastectomies. Histology showed 112 (46%) invasive cancers, 16 (7%) ductal carcinoma in-situ (DCIS) with microinvasion, and 114 (47%) pure DCIS. Cancers were predominantly estrogen receptor positive (59%) and moderate (41%) or high grade (32%). A mean of 2 final sentinel nodes were excised (range 1-6) and 21 patients (9%) had isolated tumor cells on SLNB pathology. At 16 years median follow up (range 1-22 years), 3 patients (1.2%) developed an isolated axillary failure, and 1 had concurrent axillary and chest wall recurrences (total axillary recurrence rate 1.7%). Three of four axillary recurrences occurred in patients with moderate or high-grade estrogen receptor-positive DCIS without invasion on mastectomy histology. Median time to axillary recurrence was 70.5 months (range 29-132 months). Axillary recurrence is rare after a negative SLNB, even in the absence of adjuvant radiation. This supports the safety of forgoing additional surgery or radiation to the axilla in the early-stage breast cancer and a negative SLNB.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
前哨淋巴结阴性乳房切除术患者腋窝复发的 16 年中位随访:无放射治疗的自然史
前哨淋巴结活检(SLNB)阴性的乳房肿块切除术后腋窝复发非常罕见,这可能是由于常规使用全乳房放射治疗所致。在这项研究中,我们分析了SLNB阴性且未接受辅助放疗的乳房切除术患者的腋窝复发率。我们确定了因早期乳腺癌接受乳房切除术并行 SLNB 的女性(1999-2005 年),并纳入了病理结节阴性且未进行腋窝清扫或辅助放疗的患者。主要结果是同侧腋窝复发。共有 234 名妇女接受了 242 例乳房切除术,中位年龄为 50 岁。组织学显示,112例(46%)为浸润性癌症,16例(7%)为伴有微小浸润的原位导管癌(DCIS),114例(47%)为纯DCIS。癌症主要为雌激素受体阳性(59%)、中度(41%)或高度(32%)。最后切除的前哨结节平均为 2 个(1-6 个不等),有 21 名患者(9%)在 SLNB 病理检查中发现了孤立的肿瘤细胞。中位随访16年(1-22年不等),3名患者(1.2%)出现孤立性腋窝复发,1名患者同时出现腋窝和胸壁复发(总腋窝复发率为1.7%)。4例腋窝复发中的3例发生在雌激素受体阳性的中度或高度DCIS患者中,乳房切除术组织学检查未发现侵犯。腋窝复发的中位时间为70.5个月(29-132个月)。即使没有辅助放射治疗,SLNB 阴性后腋窝复发的情况也很罕见。这支持了早期乳腺癌和SLNB阴性患者放弃额外手术或腋窝放疗的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical breast cancer
Clinical breast cancer 医学-肿瘤学
CiteScore
5.40
自引率
3.20%
发文量
174
审稿时长
48 days
期刊介绍: Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
期刊最新文献
Editorial Board Table of Contents Clinical and Imaging Features Associated With Malignant Focal Nonmass Enhancement on Breast MRI. Real-World Outcomes of Pyrotinib-Based Therapy for HER2-Positive Breast Cancer With Brain Metastases: A Multicentre, Retrospective Analysis. Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1